Enterprise Value
3.30B
Cash
283.4M
Avg Qtr Burn
-89.18M
Short % of Float
12.81%
Insider Ownership
12.85%
Institutional Own.
86.15%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Taldefgrobep alfa (BHV-2000) Details Spinal muscular atrophy | Phase 3 Data readout | |
Troriluzole (BHV-4157) Details Obsessive compulsive disorder | Phase 3 Data readout | |
Troriluzole Details Spinocerebellar Ataxia | Phase 3 Update | |
BHV-7000 Details Bipolar disease, Epilepsy | Phase 2/3 Data readout | |
BHV-7000 Details Major depressive disorder | Phase 2 Data readout | |
Phase 2 Initiation | ||
BHV-2100 [TRPM3 Antagonist] Details Migraines | Phase 2 Initiation | |
BHV-8000 [TYK2/JAK1 Inhibitor] Details Central nervous system illness | Phase 2 Initiation | |
BHV-1510 Details Cancer, Epithelial Tumors | Phase 1/2 Data readout | |
BHV-1300 Details Rheumatoid arthritis | Phase 1 Data readout |